Tero Aittokallio profile picture
Tero
Aittokallio
InFLAMES Flagship
Docent, Faculty of Science
PhD

Contact

Tykistökatu 6 A
20520
Turku

Biography

Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.

Teaching

Computational statistics.

Scientific computing.

Research

Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.

Publications

Sort by:

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy (2019)

Nature Communications
Haikala HM, Anttila JM, Marques E, Raatikainen T, Ilander M, Hakanen H, Ala-Hongisto H, Savelius M, Balboa D, Von Eyss B, Eskelinen V, Munne P, Nieminen AI, Otonkoski T, Schuler J, Laajala TD, Aittokallio T, Sihto H, Mattson J, Heikkila P, Leidenius M, Joensuu H, Mustjoki S, Kovanen P, Eilers M, Leverson JD, Klefstrom J, Klefstrom J
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL (2019)

Cancers
Linus Wahnschaffe, Till Braun, Sanna Timonen, Anil K. Giri, Alexandra Schrader, PreranaWagle, Henrikki Almusa, Patricia Johansson, Dorine Bellanger, Cristina López, Claudia Haferlach, Marc-Henri Stern, Jan Dürig, Reiner Siebert, Satu Mustjoki, Tero Aittokallio, Marco Herling
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target (2018)

Nature Communications
Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmaki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S, Mustjoki S
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells (2018)

Science Translational Medicine
Otto Kauko, Caitlin M. O’Connor, Evgeny Kulesskiy, Jaya Sangodkar, Anna Aakula, Sudeh Izadmehr, Laxman Yetukuri, Bhagwan Yadav, Artur Padzik, Teemu Daniel Laajala, Pekka Haapaniemi, Majid Momeny, Taru Varila, Michael Ohlmeyer, Tero Aittokallio, Krister Wennerberg, Goutham Narla, Jukka Westermarck
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))